Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver

Digestive and Liver Disease

Volumn 44, Issue 8, 2012, Pages 674-680

  Gramenzi, Annagiulia ^a   Conti, Fabio ^a   Cammà, Calogero ^a   Grieco, Antonio ^a   Picciotto, Antonino ^a   Furlan, Caterina ^a   Romagno, Domenico ^a   Costa, Paolo ^a   Rendina, Maria ^a   Ancarani, Fausto ^a   Chiaramonte, Maria ^a   Verucchi, Gabriella ^a   Craxì, Antonio ^a   Bernardi, Mauro ^a   Andreone, Pietro ^a   Autolitano, A ^b   Baiguera, C ^b   Balsano, C ^b   Bandiera, F ^b   Basso, M ^b   Bertoni, R ^b   Orlandini, A ^b   Biliotti, E ^b   Taliani, G ^b   Bruni, A ^b   Canovari, B ^b   Petrelli, E ^b   Caprara, C ^b   Cerrato, C ^b   Chessa, Luchino ^b   Cozzolongo, R ^b   De Gioia, S ^b   De Nicola, S ^b   De Stefano, G ^b   Ferrara, F ^b   Floreani, A ^b   Freni, MA ^b   Tortorella, V ^b   Galati, G ^b   Picardi, A ^b   Gentile, P ^b   Maio, P ^b   Maracci, M ^b   Martines, D ^b   Miele, L ^b   Vero, V ^b   Mondello, L ^b   Nosotti, L ^b   Delle, M ^b   Palvarini, L ^b   Piergentili, B ^b   Ridolfi, F ^b   Smirne, C ^b   Tonello, N ^b   Stanzione, M ^b   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

Aged patients; Epidemiology; HCV infection; Liver diseases

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN;

AGED; ANTIVIRAL THERAPY; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MONOTHERAPY; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; VIRUS LOAD;

EID: 84863783767     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.03.009     Document Type: Article

References (42)

1. Lauer G.M., Walker B.D. Hepatitis C virus infection. N Engl J Med 2001, 345:41-52.
2. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
3. Alter M.J. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007, 13:2436-2441.
4. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000, 20:17-35.
5. Armstrong G.L., Alter M.J., McQuillan G.M., et al. The past incidence of Hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000, 31:777-782.
6. Davis G.L., Alter M.J., El-Serag H., et al. Aging of the hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-521.
7. Alter M.J. Epidemiology of hepatitis C. Hepatology 1997, 26(Suppl.):62-65.
8. Spada E., Mele A., Ciccozzi M., et al. Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy. Dig Liver Dis 2001, 33:778-784.
9. Deuffic S., Buffat L., Poynard T., et al. Modeling the hepatitis C virus epidemic in France. Hepatology 1999, 29:1596-1601.
10. Mariano A., Scalia Tomba G., Tosti M.E., et al. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis 2009, 41:689-699.
11. United Nations Population Fund. Population ageing and development: social, health and gender issues. Population and development strategies series. Report No. 3. New York: United Nations Population Fund 2002.
12. Thabut D., Le Calvez S., Thibault V., et al. Hepatitis C in 6,865 persons 65yr or older: a severe and neglected curable disease. Am J Gastroenterol 2006, 101:1260-1267.
13. D'Souza R., Glynn M.J., Ushiro-Lumb I., et al. Prevalence of hepatitis C cirrhosis in elderly Asian patients infected during childhood. Clin Gastroenterol Hepatol 2005, 3:840-842.
14. Gramenzi A., Conti F., Felline F., et al. Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study. J Viral Hepat 2009, 17:360-366.
15. Campello C., Poli A., Dal M.G., et al. Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy. Infection 2002, 30:7-12.
16. Sagnelli E., Stroffolini T., Mele A., et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol 2005, 75:522-527.
17. Cozzolongo R., Osella A.R., Elba S., et al. Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol 2009, 104:2740-2746.
18. Gaiani S., Gramantieri L., Venturoli N., et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol 1997, 27:979-985.
19. Bruix J., Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
20. Wise M., Bialek S., Finelli L., et al. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008, 47:1128-1135.
21. Orimo H., Ito H., Suzuki T., et al. Reviewing the definition of elderly. Geriat Geront Int 2006, 6:149-158.
22. Poynard T., Ratziu V., Charlotte F., et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001, 34:730-739.
23. Yu M.W., Chang H.C., Chang S.C., et al. Role of reproductive factors in hepatocellular carcinoma: impact on hepatitis B- and C-related risk. Hepatology 2003, 38:1393-1400.
24. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
25. Farinati F., Sergio A., Giacomin A., et al. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2009, 21:1212-1218.
26. Chiaramonte M., Stroffolini T., Vian A., et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999, 85:2132-2137.
27. Guadagnino V., Stroffolini T., Rapicetta M., et al. Prevalence, risk factors and genotype distribution of hepatitis C virus infection in the general population. A community-based survey in Southern Italy. Hepatology 1997, 26:1006-1011.
28. Kanwal F., Schnitzler M.S., Bacon B.R., et al. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med 2010, 153:231-239.
29. Tsui J.I., Currie S., Shen H., et al. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 study. Dig Dis Sci 2008, 53:809-814.
30. Stroffolini T., Spadaro A., Guadagnino V., et al. Current practice of hepatitis C treatment in Southern Italy. Dig Liver Dis 2010, 42:822-825.
31. National Institute of Health. NIH Consensus Statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002, 19:1-46.
32. Craxì A. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264.
33. Van Spall H.G.C., Toren A., Kiss A., et al. Eligibility criteria of randomized controlled trials published in High-Impact General Medical Journals. A systematic sampling review. JAMA 2007, 297:1233-1240.
34. Giannini E.G., Basso M., Savarino V., et al. Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. Dig Dis Sci 2010, 55:3193-3199.
35. Oze T., Hiramatsu N., Yakushijin T., et al. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. J Hepatol 2011, 54:604-611.
36. Nishiguchi S., Shiomi S., Nakatani S., et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001, 357:196-197.
37. Gramenzi A., Andreone P., Fiorino S., et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001, 48:843-848.
38. Cammà C., Giunta M., Andreone P., et al. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001, 34:593-602.
39. Bruno S., Stroffolini T., Colombo M., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007, 45:579-587.
40. Cardoso A.C., Moucari R., Figueiredo-Mendes C., et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010, 52:652-657.
41. Vukotic R., Gramenzi A., Vitale G., et al. Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin. Liver Int 2008, 28:407-411.
42. Morgan T.R., Ghany M.G., Kim H.Y., et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010, 52:833-844.